Svetlana Mojsov: GLP-1's Role in Diabetes & Obesity Drug Development

Understanding GLP-1 and Its Discovery

• 💡 GLP-1 is a peptide secreted in the intestine after a meal, which then stimulates insulin secretion from the pancreas and lowers blood glucose levels.
• 🔬 In the 1970s, Svetlana Mojsov's research identified the biologically active sequence of GLP-1 and demonstrated its role as an incretin with therapeutic potential for diabetes.
• 🧪 Her experimental strategy involved synthesizing GLP-1, developing accurate analytical methods, and using a rat animal model to prove its potent, glucose-dependent insulin-stimulating effects.

Key Milestones in GLP-1 Drug Development

• 🚀 The first GLP-1 analog, Byetta, introduced in 2005, was derived from lizard saliva and demonstrated that peptides could be used as medicines.
• 💊 In 2006, DPP-4 inhibitors were developed to prolong the half-life of endogenous GLP-1, offering a GLP-1-based medicine that suppressed hypoglycemia.
• ✨ Liraglutide (Victoza), developed in 2010, extended GLP-1's half-life through lipid conjugation and was later approved for weight loss (Saxenda) in 2015.

Advancements in Obesity Treatment

• 📈 Semaglutide (Ozempic), introduced in 2017, further extended GLP-1's half-life to one week and led to an unprecedented 15% weight loss in patients.
• 🎯 The latest milestone in 2022 is Tirzepatide (Zepbound/Mounjaro), a novel peptide combining GLP-1 and GIP sequences, which has shown over 20% weight loss and is considered the new gold standard.
• 🌱 Future research focuses on combining GLP-1 with other pancreatic and intestinal peptides to achieve even higher weight loss.

Broader Therapeutic Potential

• 🧠 GLP-1 has shown potential influence on drug addiction and positive effects on cardiovascular disorders and kidney function, with some applications already approved.
• 🔍 There are also reports suggesting its influence on Parkinson's disease, though these studies are on a small scale, and the biological mechanisms in the brain are still being investigated.

Ethical Considerations for GLP-1 Drugs

• ⚠️ Svetlana Mojsov strongly believes these drugs should be used only by patients with obesity, which she identifies as a serious chronic condition, not for cosmetic weight loss.
• 💰 The shortage of GLP-1 drugs is partly attributed to off-label cosmetic use, impacting obese patients who need them.
• ✅ It is crucial to focus on making these medications affordable and ensuring they are covered by insurance, especially in places like the United States.